報價延遲最少15分鐘:2024/12/25 00:42 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.06 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.11/3.95
|
|
企業價值
2.17B
|
| 資產負債 |
|
每股賬面淨值
10.46
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
582.02M
|
|
每股收益
9.50
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 00:42 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX(pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |